May 21, 2019
Cala Health, a wearable neuromodulation therapy startup focused on chronic diseases, has closed a $50 million Series C financing round.
Novartis, Baird Capital, LifeSci Venture Partners, TriVentures and other unnamed backers participated, as did returning investors JJDC, Lux Capital, Lightstone Ventures, Action Potential Venture Capital, dRx Capital and GV.
WHAT THEY DO
June 14, 2017
San Francisco-based Omada Health has raised $50 million in new funding, led by commercial partner Cigna. Civilization Ventures and Sanofi Genzyme BioVentures also contributed to the round. Omada last raised money in September 2015, when it took in $48 million. This latest round brings the company’s total funding to $127.5 million.
Along with the funding, Cigna will also expand its collaboration...
June 13, 2016
Two of the biggest IPOs in digital health lately have come out of the wearable and telehealth spaces. But those aren't the spaces at least two seasoned digital health investors are most excited about. At BIO 2016 in San Francisco last week, Casper de Clerq, a general partner at Norwest Venture Partners, and Dr. Lucian Iancovici, a general partner at dRx Capital, Qualcomm and Novartis' joint...
October 21, 2015
Los Angeles-based mobile clinical trials company Science 37 has raised $6.5 million from Lux Capital and dRx Capital, a joint venture of Qualcomm and Novartis that launched in January.
The funding will help the company develop and roll out its novel clinical trial operating model, which uses mobile technology to allow patients to participate in the trial from their homes. The company draws on ...